PUMA BIOTECHNOLOGY INC (PBYI) Fundamental Analysis & Valuation

NASDAQ:PBYI • US74587V1070

6.22 USD
+0.17 (+2.81%)
At close: Mar 9, 2026
6.1 USD
-0.12 (-1.93%)
After Hours: 3/9/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PBYI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

PBYI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. PBYI scores excellent on profitability, but there are some minor concerns on its financial health. PBYI has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

7

1. PBYI Profitability Analysis

1.1 Basic Checks

  • PBYI had positive earnings in the past year.
  • PBYI had a positive operating cash flow in the past year.
  • In multiple years PBYI reported negative net income over the last 5 years.
  • In multiple years PBYI reported negative operating cash flow during the last 5 years.
PBYI Yearly Net Income VS EBIT VS OCF VS FCFPBYI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

  • PBYI has a better Return On Assets (18.23%) than 96.34% of its industry peers.
  • PBYI has a better Return On Equity (32.08%) than 97.30% of its industry peers.
  • The Return On Invested Capital of PBYI (22.07%) is better than 98.07% of its industry peers.
  • PBYI had an Average Return On Invested Capital over the past 3 years of 17.97%. This is in line with the industry average of 19.44%.
  • The last Return On Invested Capital (22.07%) for PBYI is above the 3 year average (17.97%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 18.23%
ROE 32.08%
ROIC 22.07%
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
PBYI Yearly ROA, ROE, ROICPBYI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • The Profit Margin of PBYI (17.44%) is better than 92.87% of its industry peers.
  • With an excellent Operating Margin value of 15.83%, PBYI belongs to the best of the industry, outperforming 92.68% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PBYI has grown nicely.
  • The Gross Margin of PBYI (76.91%) is better than 84.01% of its industry peers.
  • PBYI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 15.83%
PM (TTM) 17.44%
GM 76.91%
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
PBYI Yearly Profit, Operating, Gross MarginsPBYI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PBYI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PBYI is creating value.
  • There is no outstanding debt for PBYI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PBYI Yearly Shares OutstandingPBYI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PBYI Yearly Total Debt VS Total AssetsPBYI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -4.83, we must say that PBYI is in the distress zone and has some risk of bankruptcy.
  • PBYI has a worse Altman-Z score (-4.83) than 63.39% of its industry peers.
  • PBYI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.79
Altman-Z -4.83
ROIC/WACC2.26
WACC9.75%
PBYI Yearly LT Debt VS Equity VS FCFPBYI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

  • A Current Ratio of 1.74 indicates that PBYI should not have too much problems paying its short term obligations.
  • PBYI's Current ratio of 1.74 is on the low side compared to the rest of the industry. PBYI is outperformed by 79.00% of its industry peers.
  • A Quick Ratio of 1.62 indicates that PBYI should not have too much problems paying its short term obligations.
  • PBYI has a worse Quick ratio (1.62) than 79.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.62
PBYI Yearly Current Assets VS Current LiabilitesPBYI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. PBYI Growth Analysis

3.1 Past

  • The earnings per share for PBYI have decreased by 0.00% in the last year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.75%

3.2 Future

  • The Earnings Per Share is expected to decrease by -10.16% on average over the next years. This is quite bad
  • The Revenue is expected to decrease by -0.50% on average over the next years.
EPS Next Y-58.2%
EPS Next 2Y-8.56%
EPS Next 3Y-9.04%
EPS Next 5Y-10.16%
Revenue Next Year-1.58%
Revenue Next 2Y-0.79%
Revenue Next 3Y-0.53%
Revenue Next 5Y-0.5%

3.3 Evolution

PBYI Yearly Revenue VS EstimatesPBYI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
PBYI Yearly EPS VS EstimatesPBYI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

6

4. PBYI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 10.20, which indicates a very decent valuation of PBYI.
  • 97.50% of the companies in the same industry are more expensive than PBYI, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.46, PBYI is valued rather cheaply.
  • A Price/Forward Earnings ratio of 24.39 indicates a rather expensive valuation of PBYI.
  • 93.26% of the companies in the same industry are more expensive than PBYI, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.65, PBYI is valued at the same level.
Industry RankSector Rank
PE 10.2
Fwd PE 24.39
PBYI Price Earnings VS Forward Price EarningsPBYI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBYI indicates a rather cheap valuation: PBYI is cheaper than 98.65% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, PBYI is valued cheaper than 99.04% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.38
EV/EBITDA 4.81
PBYI Per share dataPBYI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • PBYI has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as PBYI's earnings are expected to decrease with -9.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.56%
EPS Next 3Y-9.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PBYI Dividend Analysis

5.1 Amount

  • PBYI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PBYI Fundamentals: All Metrics, Ratios and Statistics

PUMA BIOTECHNOLOGY INC

NASDAQ:PBYI (3/9/2026, 8:00:03 PM)

After market: 6.1 -0.12 (-1.93%)

6.22

+0.17 (+2.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners72.67%
Inst Owner Change4.1%
Ins Owners15.37%
Ins Owner Change2.47%
Market Cap316.47M
Revenue(TTM)N/A
Net Income(TTM)36.98M
Analysts43.33
Price Target5.1 (-18.01%)
Short Float %8.52%
Short Ratio8.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)142.48%
Min EPS beat(2)14.59%
Max EPS beat(2)270.37%
EPS beat(4)4
Avg EPS beat(4)237.87%
Min EPS beat(4)14.59%
Max EPS beat(4)394.12%
EPS beat(8)7
Avg EPS beat(8)129.74%
EPS beat(12)10
Avg EPS beat(12)120.97%
EPS beat(16)14
Avg EPS beat(16)232.31%
Revenue beat(2)2
Avg Revenue beat(2)3%
Min Revenue beat(2)1.23%
Max Revenue beat(2)4.77%
Revenue beat(4)4
Avg Revenue beat(4)4.4%
Min Revenue beat(4)1.23%
Max Revenue beat(4)10.36%
Revenue beat(8)7
Avg Revenue beat(8)4.18%
Revenue beat(12)10
Avg Revenue beat(12)4.08%
Revenue beat(16)13
Avg Revenue beat(16)5.33%
PT rev (1m)0%
PT rev (3m)7.14%
EPS NQ rev (1m)19.47%
EPS NQ rev (3m)17.92%
EPS NY rev (1m)24.73%
EPS NY rev (3m)25.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE 10.2
Fwd PE 24.39
P/S 1.49
P/FCF 7.38
P/OCF 7.36
P/B 2.75
P/tB 4.43
EV/EBITDA 4.81
EPS(TTM)0.61
EY9.81%
EPS(NY)0.26
Fwd EY4.1%
FCF(TTM)0.84
FCFY13.55%
OCF(TTM)0.84
OCFY13.58%
SpS4.17
BVpS2.27
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.58
Profitability
Industry RankSector Rank
ROA 18.23%
ROE 32.08%
ROCE 27.93%
ROIC 22.07%
ROICexc 102.97%
ROICexgc N/A
OM 15.83%
PM (TTM) 17.44%
GM 76.91%
FCFM 20.22%
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score7
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.79
Debt/EBITDA 0
Cap/Depr 1.11%
Cap/Sales 0.06%
Interest Coverage 4.71
Cash Conversion 96.22%
Profit Quality 115.93%
Current Ratio 1.74
Quick Ratio 1.62
Altman-Z -4.83
F-Score7
WACC9.75%
ROIC/WACC2.26
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y-58.2%
EPS Next 2Y-8.56%
EPS Next 3Y-9.04%
EPS Next 5Y-10.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.75%
Revenue Next Year-1.58%
Revenue Next 2Y-0.79%
Revenue Next 3Y-0.53%
Revenue Next 5Y-0.5%
EBIT growth 1Y3.58%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year93.13%
EBIT Next 3Y23.6%
EBIT Next 5YN/A
FCF growth 1Y825.85%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y77.42%
OCF growth 3Y23.52%
OCF growth 5Y11.7%

PUMA BIOTECHNOLOGY INC / PBYI FAQ

Can you provide the ChartMill fundamental rating for PUMA BIOTECHNOLOGY INC?

ChartMill assigns a fundamental rating of 4 / 10 to PBYI.


What is the valuation status of PUMA BIOTECHNOLOGY INC (PBYI) stock?

ChartMill assigns a valuation rating of 6 / 10 to PUMA BIOTECHNOLOGY INC (PBYI). This can be considered as Fairly Valued.


What is the profitability of PBYI stock?

PUMA BIOTECHNOLOGY INC (PBYI) has a profitability rating of 7 / 10.


Can you provide the financial health for PBYI stock?

The financial health rating of PUMA BIOTECHNOLOGY INC (PBYI) is 5 / 10.